Document:

Document

Exhibit 4.1

DISTRIBUTION REINVESTMENT PLAN

This Distribution Reinvestment Plan (the “Plan”) is adopted by Brookfield Real Estate Income Trust Inc. (the “Company”) pursuant to its Articles of Amendment and Restatement (as amended, restated or otherwise modified from time to time, the “Charter”). Unless otherwise defined herein, capitalized terms shall have the same meaning as set forth in the Charter.

1. Distribution Reinvestment. As agent for the stockholders (the “Stockholders”) of the Company who purchase shares of the Company’s common stock (collectively the “Shares”) pursuant to (i) the Company’s continuous public offering (the “Public Offering”), (ii) the private offering of Class E shares of the Company’s common stock pursuant to an applicable exemption from registration under the Securities Act (the “Class E Private Offering”), or (iii) any future public offering of Shares by the Company (a “Future Public Offering”), and who do not opt out of participating in the Plan or who affirmatively elect to participate in the Plan, as applicable (as set forth in Section 3 below) (the “Participants”), the Company will apply all dividends and other distributions declared and paid in respect of the Shares held by each Participant and attributable to the class of Shares held by such Participant (the “Distributions”), including Distributions paid with respect to any full or fractional Shares acquired under the Plan, to the purchase of additional Shares of the same class for such Participant.

2. Effective Date. The effective date of this Plan shall be November 2, 2021.

3. Procedure for Participation. Any Stockholder who has (i) received a Prospectus and purchased Shares pursuant to the Public Offering (unless such Stockholder is a resident of Alabama, Idaho, Kansas, Kentucky, Maine, Maryland, Massachusetts, Nebraska, New Jersey, North Carolina, Ohio, Oregon, Texas, Vermont or Washington or is a client of a participating broker-dealer that does not permit automatic enrollment in the Plan), or (ii) purchased Shares pursuant to the Class E Private Offering, will automatically become a Participant unless they elect not to become a Participant by noting such election on their subscription agreement. Any Stockholder who has received a Prospectus and purchased Shares pursuant to the Public Offering and who is a resident of Alabama, Idaho, Kansas, Kentucky, Maine, Maryland, Massachusetts, Nebraska, New Jersey, North Carolina, Ohio, Oregon, Texas, Vermont or Washington or is a client of a participating broker-dealer that does not permit automatic enrollment in the Plan will become a Participant only if they elect to become a Participant by noting such election on their subscription agreement.  If any Stockholder initially elects not to be a Participant, they may later become a Participant by subsequently completing and executing an enrollment form or any appropriate authorization form as may be available from the Company, the Company’s transfer agent, the dealer manager for the Public Offering or any soliciting dealer participating in the distribution of Shares for the Public Offering. Participation in the Plan will begin with the next Distribution payable after acceptance of a Participant’s subscription, enrollment or authorization. Shares will be purchased under the Plan on the date that Distributions are paid by the Company.

4. Suitability. Each Participant is requested to promptly notify the Company in writing if the Participant experiences a material change in his or her financial condition, including the failure to meet the income, net worth, investment concentration, status as an “accredited investor” as 

defined by Regulation D of the Securities Act (solely with respect to purchasers in the Class E Private Offering), or other investment suitability standards imposed by such Participant’s state of residence or the Company and set forth in the Company’s most recent Prospectus or the private placement memorandum with respect to the Class E Private Offering, as applicable. For the avoidance of doubt, this request in no way shifts to the Participant the responsibility of the Company’s sponsor, or any other person selling Shares on behalf of the Company to the Participant, to make every reasonable effort to determine that the purchase of Shares by stockholders who purchased Shares in the Public Offering is a suitable and appropriate investment based on information provided by such Participant.

5. Purchase of Shares. 

A.  Participants will acquire Shares from the Company (including Shares purchased by the Company for the Plan in a secondary market (if available) or on a stock exchange (if listed)) under the Plan at a price equal to the NAV per Share applicable to the class of Shares held by the Participant on the date that the Distribution is payable (calculated as of the most recent month end). No upfront selling commissions will be payable with respect to Shares purchased pursuant to the Plan. Participants in the Plan may purchase fractional Shares so that 100% of the Distributions will be used to acquire Shares. However, a Participant will not be able to acquire Shares and such Participant’s participation in the Plan will be terminated to the extent that a reinvestment of such Participant’s Distributions in Shares would cause the percentage ownership or other limitations contained in the Charter to be violated.

B.   Shares to be distributed by the Company in connection with the Plan may (but are not required to) be supplied from: (i) the Shares registered with the SEC in connection with the Public Offering, (ii) Class E shares issued by the Company pursuant to an applicable exemption from registration under the Securities Act, or (iii) Shares to be registered with the SEC in a Future Public Offering for use in the Plan.

6. Taxes. THE REINVESTMENT OF DISTRIBUTIONS DOES NOT RELIEVE A PARTICIPANT OF ANY INCOME TAX LIABILITY THAT MAY BE PAYABLE IN RESPECT OF THE DISTRIBUTIONS. INFORMATION REGARDING POTENTIAL TAX INCOME LIABILITY OF PARTICIPANTS MAY BE FOUND IN THE PUBLIC FILINGS MADE BY THE COMPANY WITH THE SEC.

7. Share Certificates. The ownership of the Shares purchased through the Plan will be in book-entry form unless and until the Company issues certificates for its outstanding Shares.

8. Reports. On a quarterly basis, the Company shall provide each Participant a statement of account describing, as to such Participant: (i) the Distributions reinvested during the quarter; (ii) the number and class of Shares purchased pursuant to the Plan during the quarter; (iii) the per share purchase price for such Shares; and (iv) the total number of Shares purchased on behalf of the Participant under the Plan. On an annual basis, tax information with respect to income earned on Shares under the Plan for the calendar year will be provided to each applicable participant.

9. Termination by Participant. A Participant may terminate participation in the Plan at any time, without penalty, by delivering 10 days’ prior written notice to the Company. This notice must be received by the Company prior to the last day of a month in order for a Participant’s 

termination to be effective for such month (i.e., a timely termination notice will be effective as of the last day of a month in which it is timely received and will not affect participation in the Plan for any prior month). Any transfer of Shares by a Participant to a non-Participant will terminate participation in the Plan with respect to the transferred Shares. If a Participant requests that the Company repurchase all or any portion of the Participant’s Shares, the Participant’s participation in the Plan with respect to the Participant’s Shares for which repurchase was requested but that were not repurchased will be terminated. If a Participant terminates Plan participation, the Company may, at its option, ensure that the terminating Participant’s account will reflect the whole number of Shares in such Participant’s account and provide a check for the cash value of any fractional Share in such account. Upon termination of Plan participation for any reason, future Distributions will be distributed to the Stockholder in cash.

10. Amendment, Suspension or Termination by the Company. The Board of Directors may by majority vote amend any aspect of the Plan; provided that the Plan cannot be amended to eliminate a Participant’s right to terminate participation in the Plan and that notice of any material amendment must be provided to Participants at least 10 days prior to the effective date of that amendment. The Board of Directors may by majority vote suspend or terminate the Plan for any reason upon 10 days’ written notice to the Participants.

11. Liability of the Company. The Company shall not be liable for any act done in good faith, or for any good faith omission to act, including, without limitation, any claims or liability (i) arising out of failure to terminate a Participant’s account upon such Participant’s death prior to timely receipt of notice in writing of such death or (ii) with respect to the time and the prices at which Shares are purchased or sold for a Participant’s account. To the extent that indemnification may apply to liabilities arising under the Securities Act, or the securities laws of a particular state, the Company has been advised that, in the opinion of the SEC and certain state securities commissioners, such indemnification is contrary to public policy and, therefore, unenforceable.Exhibit 10.1

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE
COMPETITIVE HARM TO MUSCLEPHARM CORPORATION IF PUBLICLY DISCLOSED

 

FIRST
AMENDMENT TO CONFIDENTIAL SETTLEMENT AGREEMENT

 

THIS
FIRST AMENDMENT TO CONFIDENTIAL SETTLEMENT AGREEMENT(“Amendment”) is entered into by and between NBF Holdings Canada
Inc. (“Nutrablend”) and MusclePharm Corporation (“MusclePharm”). (Nutrablend and MusclePharm are
referred to collectively as the “Parties,” or individually as a “Party.”) The Effective Date of
this Amendment shall be the latest date shown on the fully executed signature page(s) (“Effective Date”).

 

RECITALS

 

A.
On or about September 17, 2020, Nutrablend and MusclePharm entered into a Confidential Settlement Agreement (as amended through this
Amendment, the “Agreement”), which resolved a civil action pending in the United States District Court for the Central
District of California, captioned NBF Holdings Canada Inc. v. MusclePharm Corporation, Case No. 2:20- cv-01946-SVW-AFM (the “First
Litigation”). The Agreement contained provisions (i) requiring MusclePharm to make certain payments to Nutrablend on a schedule
set forth in the Agreement (the “Monthly Payments”); and (ii) requiring MusclePharm to issue certain purchase orders
to Nutrablend on a schedule set forth in the Agreement (the “Purchase Orders”).

 

B.
The Parties agree that MusclePharm has made all Monthly Payments due since the Effective Date of the Agreement, through to the Effective
Date of this Amendment (including all Monthly Payments due in the First, Second, Third and Fourth Pay Periods (as each such term is defined
below), and the first payment due in the Fifth Pay Period (as defined below)). MusclePharm hereby reaffirms its obligation to continue
making Monthly Payments as required by and as set forth in the Agreement.

 

C.
After execution of the Agreement, a dispute arose between Nutrablend and MusclePharm concerning the parties’ performance of their
respective obligations under the provisions of the Agreement (the “Purchase Order Provisions”) relating to the issuance
and fulfillment of the Purchase Orders.

 

D.
On July 7, 2021, MusclePharm commenced an action against Nutrablend in the United States District Court for the Central District of California,
captioned MusclePharm Corporation v. NBF Holdings Canada Inc., Case No. 2:21-cv-05504-MCS-RAO (the “Second Litigation”).

 

E.
The Parties recognize the cost, burden, and uncertainty of litigation, as well as the extended period of time that it will likely take
to resolve the dispute through litigation, and have independently concluded that their respective interests would be best served by compromising
and concluding all corresponding disputes between them regarding the Purchase Order Provisions and the Purchase Orders. Accordingly,
the Parties desire to resolve and settle their disputes and all claims, counterclaims, and causes of action that were or could have been
asserted in the Litigation, by (i) terminating all Purchase Order Provisions (and the Parties’ obligations related thereto) under
the Agreement; and (ii) reaffirming the Parties’ obligations relating to the Owed Amount (as defined in the Agreement) and Monthly
Payments.

 

F.
The Parties acknowledge that they are entering into this Amendment voluntarily and after consultation with counsel of their choosing.

 

    	1

     

    

 

NOW,
THEREFORE, in consideration of these promises and the mutual covenants set forth herein and for valuable and mutual consideration, and
in consideration of the foregoing recitals (“Recitals”), the Parties agree as follows in order to fully and finally
resolve the dispute:

 

1.
Recitals. The foregoing Recitals are expressly incorporated as part of the Amendment, and the Parties confirm and represent to
one another that said Recitals are true and correct to the best of their knowledge, information, and belief.

 

2.
Purchase of Packaging and Materials. MusclePharm agrees to purchase from Nutrablend the materials set forth in Exhibit A
hereto (the “Materials”) and the packaging set forth in Exhibit B hereto (the “Packaging”),
in accordance with the following terms:

 

(a)
Invoices and Payment. Nutrablend shall issue invoices for the materials and packaging on or before September 30, 2021. The total
purchase price for the Materials and Packaging shall be [***](the “Purchase Price”). MusclePharm shall pay the Purchase
Price in the following two installments: (a) [***]due on October 29, 2021; and (b) [***]due on November 29, 2021.

 

(b)
Shipment and Freight. MusclePharm shall identify for Nutrablend on or before September 24, 2021 which of the Materials and Packaging
that it wishes to take into its possession (the “Identified Items”). Nutrablend shall ship the Identified Items to
MusclePharm on or before September 30, 2021. MusclePharm shall bear the freight costs relating to the Identified Items.

 

(c)
Disposal of Unused Items. Nutrablend may use or destroy, at its option, any Materials or Packaging that MusclePharm does not identify
in Section 2(b) above, except that Nutrablend shall destroy all Materials or Packaging containing any logos, labeling or other intellectual
property belonging or related to MusclePharm or MusclePharm’s products. For the avoidance of doubt, the Purchase Price shall not
be reduced due to MusclePharm identifying fewer than all of the Materials and Packaging pursuant to Section 2(b), or due to Nutrablend
using any Materials or Packaging that MusclePharm does not identify pursuant to Section 2(b).

 

3.
Amendments to the Agreement

 

(a)
Amendment to Section 2. Section 2 of the Agreement is hereby deleted and replaced in its entirety with the following:

 

2.
Consideration. In consideration for Nutrablend’s promises and covenants contained herein, MusclePharm agrees and admits
that it owes Nutrablend the total, and outstanding, amount of three million eighty five thousand six hundred forty one U.S. Dollars and
fifty two cents ($3,085,641.52) (“Owed Amount”).1 MusclePharm further

 

 

1
Nutrablend acknowledges that it has received from MusclePharm all payments due during the First, Second, Third and Fourth Pay Period
(as defined below), and the first payment due during the Fifth Pay Period (as defined below), such that the Owed Amount as of the date
of this Amendment has been reduced to $2,095,641.52. agrees to pay the Owed Amount to Nutrablend in monthly payments (“Monthly
Payments”), according to the following schedule:

 

    	2

     

    

 

 

(a)
September 1, 2020 through November 30, 2020 (“First Pay Period”): MusclePharm will pay [***]to Nutrablend, in three equal
payments of [***]U.S. Dollars on or before each of September 1 (or immediately thereafter as the Agreement is fully executed by the parties),
October 1, and November 1, 2020. Nutrablend acknowledges that it has received from MusclePharm all payments due during the First Pay
Period.

 

(b)
December 1, 2020 through February 28, 2021 (“Second Pay Period”): MusclePharm will pay [***]U.S. Dollars, in three equal
payments of [***]U.S. Dollars on or before each of December 1, 2020, January 1 and February 1, 2021. Nutrablend acknowledges that it
has received from MusclePharm all payments due during the Second Pay Period.

 

(c)
March 1, 2021 through May 31, 2021 (“Third Pay Period”): MusclePharm will pay [***]U.S. Dollars to Nutrablend, in three equal
payments of [***]U.S. Dollars on or before each of March 1, April 1, and June 1, 2021. Nutrablend acknowledges that it has received from
MusclePharm all payments due during the Third Pay Period.

 

(d)
June 1, 2021 through August 31, 2021 (“Fourth Pay Period”): MusclePharm will pay [***]U.S. Dollars to Nutrablend, in three
equal payments of [***]U.S. Dollars on or before each of June 1, July 1, and August 1, 2021. Nutrablend acknowledges that it has received
from MusclePharm all payments due during the Fourth Pay Period.

 

(e)
September 1, 2021 through October 30, 2021 (“Fifth Pay Period”): MusclePharm will pay [***]U.S. Dollars to Nutrablend, in
two equal payments of [***]U.S. Dollars on or before each of September 1 and October 1, 2021. Nutrablend acknowledges that it has received
from MusclePharm the payment due on September 1, 2021.

 

(f)
Beginning November 1, 2021, MusclePharm will pay [***] U.S. Dollars per month, due on or before the first day of each month (each a “Subsequent
Pay Period,” and together with the First, Second, Third, Fourth or Fifth Pay Periods, the “Pay Periods”), to Nutrablend
until the Owed Amount is paid in full to Nutrablend.

 

(g)
The Monthly Payments shall be delivered to Nutrablend beginning on September 1, 2020, or immediately thereafter as the Agreement is fully
executed by the parties, and shall be made by wire transfer pursuant to the “Wire Payment Services” information attached
hereto as Exhibit A.

 

(h)
Upon payment in full of the Owed Amount by MusclePharm, all then-existing and future obligations under this Agreement to make Monthly
Payments shall cease.

 

    	3

     

    

 

(b)
Amendment to Section 3. Section 3 of the Agreement is hereby deleted and replaced in its entirety with the following:

 

3.
Event of Default. Any breach by MusclePharm of this Agreement that remains uncured after five business days’ written notice
will be considered an “Event of Default.” The Parties agree that, any failure by MusclePharm to make timely payment of any
of the Monthly Payments shall constitute a breach of this Agreement and an Event of Default. Notwithstanding the foregoing, it is hereby
agreed that the failure by MusclePharm to make a payment required by this Agreement shall not be an Event of Default unless such failure
is greater than 10% of the required payment. Upon the occurrence of an Event of Default, the unpaid balance of the Owed Amount shall
be accelerated, and become immediately due and payable by MusclePharm to Nutrablend, and Nutrablend shall have the authority to initiate
a legal proceeding pursuant to the “Enforcement” provision below to enforce this Agreement. Further, in the Event of Default,
and only in the Event of a Default, Nutrablend shall be entitled to, and MusclePharm agrees that Nutrablend may, submit, file, and enter
the Stipulated Judgment attached hereto as Exhibit B, or such other pleading as the court may require. Nutrablend will be entitled to
recover its reasonable court costs and attorneys’ fees from MusclePharm in connection with such actions due to MusclePharm’s
breach of this Agreement.

 

(c)
Amendment to Section 4. Section 4 of the Agreement is hereby deleted in its entirety.

 

4.
Mutual Limited Release. In exchange for legally sufficient consideration as described herein, the Parties hereby fully, finally,
and mutually generally release each of the other from any and all claims that do, or may, exist as between them, as follows:

 

(a)
As of the Effective Date, Nutrablend, on its own behalf and on behalf of its shareholders, directors, officers, employees, agents, legal
representatives, affiliates, parents, predecessors, successors, insurers, subsidiaries and sibling corporations and entities, heirs,
assigns, and anyone else acting on its behalf (the “Nutrablend Releasors”), hereby generally, voluntarily and knowingly,
absolutely, irrevocably, broadly and unconditionally fully and forever release and discharge MusclePharm, and its shareholders, directors,
officers, employees, agents, legal representatives, affiliates, parents, predecessors, successors, insurers, subsidiaries and sibling
corporations and entities, heirs, assigns, and anyone else acting on its behalf (the “MusclePharm Releasees”), of
and from any and all liability, claims, demands, damages, punitive damages, disputes, suits and action, in law or in equity, whether
known or unknown, suspected or unsuspected, or foreseen or unforeseen, of any kind or nature whatsoever, that were or that could have
been alleged in any court of other forum, which Nutrablend now or hereafter can, shall, or may have arising out of, relating to, or assertable
in connection with the Purchase Order Provisions of the Agreement. For the avoidance of doubt, nothing herein shall release the MusclePharm
Releasees from any obligations they have as set forth in this Amendment, and as set forth in the Agreement as amended by this Amendment,
including to make Monthly Payments as set forth in the Agreement.

 

    	4

     

    

 

(b)
As of the Effective Date, MusclePharm, on its own behalf and on behalf of its shareholders, directors, officers, employees, agents, legal
representatives, affiliates, parents, predecessors, successors, insurers, subsidiaries and sibling corporations and entities, heirs,
assigns, and anyone else acting on its behalf (the “MusclePharm Releasors”), hereby generally, voluntarily and knowingly,
absolutely, irrevocably, broadly and unconditionally fully and forever releases and discharges Nutrablend and its shareholders, directors,
officers, employees, agents, legal representatives, affiliates, parents, predecessors, successors, insurers, subsidiaries and sibling
corporations and entities, heirs, assigns, and anyone else acting on its behalf (the “Nutrablend Releasees”), of and
from any and all liability, claims, demands, damages, punitive damages, disputes, suits and action, in law or in equity, whether known
or unknown, suspected or unsuspected, or foreseen or unforeseen, of any kind or nature whatsoever, that were or that could have been
alleged in any court of other forum, which MusclePharm now or hereafter can, shall, or may have arising out of, relating to, or assertable
in connection with the Purchase Order Provisions of the Agreement. For the avoidance of doubt, nothing herein shall release the MusclePharm
Releasees from any obligations they have as set forth in this Amendment, and as set forth in the Agreement as amended by this Amendment.

 

(c)
The releases stated in Paragraph 4(a) and 4(b) of this Amendment will be referred to as the “Released Claims.” Excluded from
these releases are: (i) claims that cannot be waived by law, if any; and (ii) claims for enforcement of this Amendment or the Agreement
as amended by this Amendment.

 

(d)
Except for the obligations under this Amendment and under the Agreement as amended by this Amendment, the MusclePharm Releasors and the
Nutrablend Releasors (together, the “Releasors”) agree that their releases expressly waive and release any and all
provisions, rights, and benefits conferred by § 1542 of the California Civil Code, which states:

 

A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY;

 

or
of any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to
§ 1542 of the California Civil Code. Each Releasor may hereafter discover facts other than or different from those which he, she,
or it knows or believes to be true with respect to the Released Claims which are the subject matter of the provisions of Paragraph 4
of this Amendment, but each Releasor hereby expressly waives and fully, finally, and forever settles and releases, upon this Amendment
becoming final, any known or unknown, suspected or unsuspected, contingent or non-contingent claim with respect to the subject matter
of the provisions of Paragraph 4 of this Amendment, whether or not concealed or hidden, without regard to the subsequent discovery or
existence of such different or additional facts.

 

5.
Dismissal of Litigation. Within five (5) business days of the Effective Date, MusclePharm shall file a Notice of Dismissal in
the Second Litigation, with the consent and agreement of Nutrablend, dismissing all claims asserted in the Second Litigation with prejudice.
Each Party shall bear its own attorney’s fees and expenses incurred in connection with the Second Litigation and the drafting of
this Amendment.

 

    	5

     

    

 

6.
No Other Pending Claims. The Parties agree and represent that they have no other pending legal actions or claims against each
other, including in any court, arbitration forum, governmental or administrative forum or agency, or other dispute resolution forum that
are in any way related to the Second Litigation or dispute described herein.

 

7.
Settlement Not an Admission. It is expressly understood that this Amendment and the settlement it represents are entered into
solely for the purpose of allowing the Parties to avoid further litigation. This Amendment does not constitute an admission by either
Party of any wrongdoing, preexisting contractual obligation, or of any duty whatsoever, whether based in statute, regulation, common
law, or otherwise, and each Party expressly denies that any liability or any such violation has occurred.

 

8.
Representations. Each Party represents and warrants that it has the full power, capacity and authority to enter into this Agreement,
that it has not sold, transferred, conveyed, assigned, or otherwise disposed of any right, title or interest in any of the Released Claims
herein to any person or entity, and that each of the Parties is not aware of any other person or entity who may have or who has asserted
or can assert a right, title, or interest in any of the Released Claims covered by this Agreement. The Parties further affirm that the
Parties are fully capable of executing this Agreement and understand its contents and, further, that the Parties have legal counsel of
their own choice to explain the legal effect of signing this Agreement.

 

9.
Confidentiality. The Parties agree that this Amendment, as well as the nature and terms of this settlement and the subject matter
thereof, will be forever treated as confidential and the Parties shall make no disclosure or reference to the terms of this Amendment
to any person or entity, except to the Parties’ respective attorneys and, as necessary, auditors and/or tax preparers, provided
that each such person agrees to be bound by the confidential nature of this Amendment. The Parties and their counsel may also make such
disclosures pursuant to court or administrative order, subpoena, or as otherwise may be required by law. MusclePharm shall also be permitted
to file with or furnish to the Securities and Exchange Commission (the “Commission”) any specific disclosure of this Amendment
or the terms or substance thereof or include this Amendment as an exhibit to any report, statement or other document filed with or furnished
to the Commission if (a) MusclePharm receives a written or oral comment from the Commission requiring MusclePharm to make any such disclosure;
or (ii) MusclePharm believes in good faith, including upon the advice of counsel or its auditors, that MusclePharm is required to make
any such disclosure of this Amendment or the terms or substance thereof in any such report, statement or other document, including pursuant
to Regulation S-K, Regulation S-X or other applicable accounting standards or interpretations or to prevent a material misstatement in
or omission of a material fact from any filing or other disclosure made by it; provided, that, to the extent that MusclePharm believes
that it can do so in good faith, in connection with any public filing of this Amendment as an Exhibit with the Commission, MusclePharm
shall seek confidential treatment of those portions of this Amendment for which it in good faith believes confidential treatment is appropriate
under the Commission’s standards for granting confidential treatment. The Parties acknowledge and agree that the Parties’
promises to maintain the confidentiality of the Amendment are an important element of the consideration for and inducement of the Parties
to enter into this Amendment. The Parties further agree that any Party’s breach of this Amendment’s confidentiality clause
constitutes irreparable harm to the other Party. In the event of an actual or threatened confidentiality breach, the Parties consent
to a temporary restraining order, preliminary injunction, and/or permanent injunction prohibiting commission or continuation of any actual
or threatened breach. Nothing in this Amendment shall preclude the Parties from stating, in response to any inquiry, that this dispute
has been resolved by mutual agreement and to the mutual satisfaction of the Parties, and in MusclePharm’s case that it is no longer
obligated to issue Purchase Orders to Nutrablend, but it is expressly agreed that the Parties shall make no further comment.

 

    	6

     

    

 

10.
Entire Agreement. Together with the Agreement (as amended by this Amendment), this Amendment comprises the entire agreement between
the Parties and supersedes any and all prior oral and written agreements between them. The Agreement and this Amendment may not be altered,
amended, or modified except by a further writing signed by the Parties.

 

11.
Severability. Should any clause, sentence, paragraph or other part of this Amendment be finally adjudged by any court of competent
jurisdiction to be invalid or in any way unenforceable, such adjudication shall not affect, impair, invalidate or nullify the remainder
of the Amendment, but shall affect only the clause, sentence, paragraph or other parts so adjudged.

 

12.
Amendment Jointly Negotiated. Each Party acknowledges that this Amendment was jointly negotiated and prepared. The Amendment shall
not be construed by any court of law or equity against any party solely by virtue of any party having drafted this Amendment.

 

13.
Governing Law and Venue. The Parties agree that this Amendment, as with the Agreement, shall not be governed by the 1980 UN Convention
on Contracts for the International Sale of Goods. Rather, this Amendment, as with the Agreement, shall be governed by, and construed
in accordance with, the laws of the State of California, without regard to choice of law or conflict of laws principles. The Parties
consent to submit to the jurisdiction of the state and/or federal courts located within Los Angeles in the State of California for resolution
of any dispute arising out of the Agreement and/or this Amendment. The Parties waive any objections to such venue.

 

14.
Opportunity to Consult Legal Counsel. The Parties confirm that they have reviewed and considered this Amendment and consulted
with their attorneys regarding the terms and effect thereof.

 

15.
Authority to Settle. Each Party represents and warrants that the person signing this Amendment has authority to bind the Party
and enter into the Amendment.

 

16.
Non-Waiver. Failure to insist upon strict compliance with any terms of this Amendment is not a waiver of such terms. The waiver
of any breach of any provision of this Amendment will not be deemed a waiver of any other breach of any provision of this Amendment.

 

17.
Signing in Counterparts. This Amendment may be signed in counterparts, each of which shall be deemed an original, but all of which
together constitute one and the same Amendment. Delivery of an executed counterpart of a signature page to this Amendment by facsimile
transmission or electronic mail shall be deemed a binding, original signature.

 

18.
THE PARTIES CERTIFY THAT EACH HAS READ ALL OF THIS AMENDMENT AND FULLY UNDERSTAND ITS TERMS.

 

    	7

     

    

 

IN
WITNESS WHEREOF, the undersigned Parties agree to each of the above terms, conditions, and provisions.

 

	 	NBF Holdings Canada Inc.
	 	 
	Date
    Executed: September 23, 2021	 	 
	 	 	Its
    Authorized Signatory
	 	Print
    Name:	 
	 	Title:	 

 

	 	MusclePharm Corporation
	 	 
	Date
    Executed: September , 2021	 	 
	 	 	Its
    Authorized Signatory
	 	Print
    Name:	 
	 	Title:	 

 

    	8

     

    

 

IN
WITNESS WHEREOF, the undersigned Parties agree to each of the above terms, conditions, and provisions.

 

	 	NBF Holdings Canada Inc.
	 	 
	Date
    Executed: September_, 2021	 	 
	 	 	its
    Authorized Signatory
	 	Print
    Name:	 
	 	Title:	 

 

	Date
    Executed: September 23, 2021	 	/s/
    Sabina Rizvi 
	 	 	its
    Authorized Signatory
	 	Print
    Name:	Sabina
    Rizvi
	 	Title:	 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]